Study of (Mirapex) Pramipexole for the Early Treatment of Parkinsons Disease (PD)
Public ClinicalTrials.gov record NCT00321854. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-blind, Placebo-controlled, Parallel-group Clinical Trial to Examine the Efficacy and Safety of Early Pramipexole (PPX) Treatment Versus Delayed Pramipexole Treatment in Patients With New Onset Parkinson's Disease.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a double blind, placebo-controlled clinical trial of 15 months duration designed to examine early Mirapex (pramipexole) treatment vs. delayed Mirapex (pramipexole) treatment in patients with new onset Parkinsons disease
Study identification
- NCT ID
- NCT00321854
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 4
- Enrollment
- 535 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 30 Years to 79 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 30, 2006
- Primary completion
- Mar 31, 2009
- Completion
- Not listed
- Last update posted
- May 15, 2014
Started 2006
United States locations
- U.S. sites
- 32
- U.S. states
- 19
- U.S. cities
- 31
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| 248.595.0122 Boehringer Ingelheim Investigational Site | Brimingham | Alabama | — | — |
| 248.595.0104 Boehringer Ingelheim Investigational Site | Scottsdale | Arizona | — | — |
| 248.595.0133 Boehringer Ingelheim Investigational Site | La Jolla | California | — | — |
| 248.595.0140 Boehringer Ingelheim Investigational Site | La Jolla | California | — | — |
| 248.595.0112 Boehringer Ingelheim Investigational Site | New Haven | Connecticut | — | — |
| 248.595.0113 Boehringer Ingelheim Investigational Site | Bradenton | Florida | — | — |
| 248.595.0105 Boehringer Ingelheim Investigational Site | Gainesville | Florida | — | — |
| 248.595.0119 Boehringer Ingelheim Investigational Site | Hollywood | Florida | — | — |
| 248.595.0124 Boehringer Ingelheim Investigational Site | Palm Beach Gardens | Florida | — | — |
| 248.595.0123 Boehringer Ingelheim Investigational Site | Panama City | Florida | — | — |
| 248.595.0109 Boehringer Ingelheim Investigational Site | South Miami | Florida | — | — |
| 248.595.0115 Boehringer Ingelheim Investigational Site | St. Petersburg | Florida | — | — |
| 248.595.0106 Boehringer Ingelheim Investigational Site | Tampa | Florida | — | — |
| 248.595.0103 Boehringer Ingelheim Investigational Site | Atlanta | Georgia | — | — |
| 248.595.0127 Boehringer Ingelheim Investigational Site | Augusta | Georgia | — | — |
| 248.595.0137 Boehringer Ingelheim Investigational Site | Columbus | Georgia | — | — |
| 248.595.0101 Boehringer Ingelheim Investigational Site | Chicago | Illinois | — | — |
| 248.595.0111 Boehringer Ingelheim Investigational Site | Elk Grove Village | Illinois | — | — |
| 248.595.0131 Boehringer Ingelheim Investigational Site | Scarbourough | Maine | — | — |
| 248.595.0134 Boehringer Ingelheim Investigational Site | Baltimore | Maryland | — | — |
| 248.595.0141 Boehringer Ingelheim Investigational Site | Worcester | Massachusetts | — | — |
| 248.595.0102 Boehringer Ingelheim Investigational Site | Traverse City | Michigan | — | — |
| 248.595.0129 Boehringer Ingelheim Investigational Site | New York | New York | — | — |
| 248.595.0139 Boehringer Ingelheim Investigational Site | Raleigh | North Carolina | — | — |
| 248.595.0136 Boehringer Ingelheim Investigational Site | Winston-Salem | North Carolina | — | — |
| 248.595.0120 Boehringer Ingelheim Investigational Site | Cleveland | Ohio | — | — |
| 248.595.0107 Boehringer Ingelheim Investigational Site | Dayton | Ohio | — | — |
| 248.595.0118 Boehringer Ingelheim Investigational Site | Tulsa | Oklahoma | — | — |
| 248.595.0114 Boehringer Ingelheim Investigational Site | Warwick | Rhode Island | — | — |
| 248.595.0116 Boehringer Ingelheim Investigational Site | Memphis | Tennessee | — | — |
| 248.595.0108 Boehringer Ingelheim Investigational Site | Houston | Texas | — | — |
| 248.595.0121 Boehringer Ingelheim Investigational Site | Kirkland | Washington | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 67 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00321854, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 15, 2014 · Synced Sep 28, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00321854 live on ClinicalTrials.gov.